"uuid:ID","studyEstimands","studyInvestigationalInterventions","bcCategories","documentVersion","id","label","name","description","studyDesignRationale"
"645c2ec8-a6c6-4ed3-8266-3a07da1ec35c","[]","[]","[]","","StudyDesign_1","","Study Design 1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
